Home » AUSTRALIAN BIOTECH ACQUIRES MYOMATRIX
AUSTRALIAN BIOTECH ACQUIRES MYOMATRIX
An Australian biotech company has acquired Myomatrix Therapeutics of Rensselaer, N.Y. Terms of the deal were not disclosed. Cytopia Inc., a wholly owned subsidiary of Cytopia Ltd., plans to add staff once the merger is completed. Shreefal Mehta, Myomatrix CEO, will be vice president of the merged entity. Myomatrix, located at the state University of New York's East Campus, and Cytopia have collaborated over the past year to develop treatments for cardiovascular disorders, including heart failure.
The Business Review
(http://www.bizjournals.com/albany/stories/2005/01/10/daily45.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May